




SIMPLIFIED DATA MANAGEMENT WITH OMNIPOD DISCOVER™

The official diabetes insights platform for Omnipod® 5
Automated Insulin Delivery System*



Reports are examples, for illustrative purposes only.

*Automated mode requires a compatible sensor. Compatible sensors are sold and prescribed separately. Sensor availability may vary by country or region.

EASY TO INTERPRET DATA TO INFORM OMNIPOD 5 OPTIMISATION

THE OMNIPOD 5 ALGORITHM IN ACTION




Omnipod 5 data is **automatically uploaded** into **Omnipod Discover** and can be accessed **at any time** to support in-person or remote clinic visits

Omnipod Discover shows how Omnipod 5 helps to proactively correct and protect^{1,2}




Auto corrects up to 4x the adaptive rate to help **proactively correct highs**



Adjusts every 5 minutes

Decreases and/or pauses insulin delivery to help **protect against lows**



Screens are examples, for illustrative purposes only.

OMNIPOD 5 USERS GET EFFORTLESS ACCESS TO THEIR DATA



Simple-to-read insights on glucose patterns and insulin trends



Insights help to understand how **certain behaviours** and pump settings directly affect glucose management



Omnipod Discover translates diabetes data into **actionable*** insights to empower Omnipod 5 users with their diabetes management

*The term "Actionable" in this context refers to acting on insights to make lifestyle changes such as adjustments in diet, physical activity, and other daily habits. It does not imply or recommend making changes to device settings.



SUMMARY

YOUR ONE-STOP RESOURCE
FOR OMNIPOD 5 OPTIMISATION

The Summary page is a comprehensive recap of the glucose and insulin data you need to identify patterns and optimise therapy. View the AGP alongside key adjustable settings and bolusing behaviours to quickly identify trends and impact glycaemic outcomes.

Glycaemic Metrics and Device Use

- Time in Ranges
- Glucose Metrics
- Device Use (Omnipod 5 and Sensor)

Ambulatory Glucose Profile (AGP)

Bolus Information

- Average Number of Boluses Per Day
- Average Number of Boluses by Time of Day

Omnipod 5 Adjustable Settings

- Target Glucose and Correct Above
- Insulin to Carb Ratio
- Correction Factor
- Duration of Insulin Action

Insulin Summary Information

- Average Total Daily Insulin
- Basal/Bolus Breakdown
- User Overrides
- Bolus Type—Meal, Correction Only, Manual
- Average Carbs/Day
- Average Carb Entries/Day

Jane Smith


DOB: 21/11/1988 (36 years old)

Omnipod Discover™

14-Day Summary

06/03/2025-20/03/2025 | Report Generated: 20/03/2025

Time in Ranges



Glucose Metrics

Average Glucose

8.7 mmol/L

Glucose Variability (CV*)

30.4% Goal: ≤36%

*Coefficient of variation

Glucose Mgmt Indicator (GMI)

7.1% Goal: <7%

Standard Deviation (SD)

2.6 mmol/L

Device Use | Omnipod 5 & Dexcom G7




Active Pod Wear Time 99%

Avg Pod Wear Time 2.4 Days (58 hrs)

Connected Sensor Time 99%

Ambulatory Glucose Profile (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if they occurred in a single day.



Bolus (Avg no. of boluses/day: 6.5)



Omnipod 5 Settings

Duration of Insulin Action 3 hrs



Insulin Summary

Avg Total Daily Insulin: 27.1 U

Basal/Day

54%


14.5 U

Bolus/Day

46%

12.6 U

Bolus Type



Avg no. of boluses/day: 6.5

User override: 4% of total boluses (4 boluses over 14 days)

Diet

Avg carbs/day

107g

Avg no. of carb entries/day

5.4



DAILY VIEW

The Daily View displays daily glucose, user-initiated bolus behaviours, microbolus auto events, and system mode details. Review daily trends to celebrate successes and identify opportunities for improvement.

Daily Glucose

- Target Glucose Settings
- Sensor Values and Trends Used
- Manually Entered Glucose

Bolus Information

- Bolus Type—Meal, Correction Only, Manual
- Units Delivered
- Carbs Entered

Insulin Delivery

- Microbolus Auto Events
- Automated Mode, Manual Mode, Limited, Activity feature, Pod changes.

Jane Smith

DOB: 21/11/1988 (36 years old)

14-Day Daily Report


06/03/2025-20/03/2025 | Report Generated: 20/03/2025

Omnipod Discover™


Legend

Glucose	Bolus	Insulin Delivery	Pod
● ● Sensor Value and Trend	▲ User Override Up	■ Meal Bolus	■ Automated
■ Manually Entered	▼ User Override Down	■ Correction Bolus Only	■ Manual
— Target Glucose	■ Extended	■ Activity	■ Max Delivery
		■ Limited	■ Insulin Paused
			■ Temp Basal
			■ Pod Change


Thursday, 06/03/2025



Friday, 07/03/2025



Saturday, 08/03/2025





SETTINGS

The Settings page shows the basal and bolus settings programmed in the patient’s Omnipod 5 Controller at the time the report is generated.

Note: The settings are listed in order of first-time setup to support switching to a new Omnipod 5 device.

Basal Settings

- Max Basal
- Basal Programmes
- Temporary Basal

Bolus Settings

- Target Glucose
- Correct Above
- Insulin to Carb Ratio
- Correction Factor
- Duration of Insulin Action
- Max Bolus
- Extended Bolus
- Min Glucose for Calculation
- Reverse Correction

Jane Smith

DOB: 21/11/1988 (36 years old)

Omnipod Discover™

Omnipod 5 Settings

SN: 01040802-000015341 | Report Generated: 20/03/2025 | This page reflects the most recent pump settings

Basal Settings

Changing Basal Programmes only impacts Manual Mode basal delivery.

Max Basal Rate 3 U/hr

Basal Programmes

	Start Time	End Time	Basal Rate
Basal 1 (Active)	00:00	19:00	0.6 U/hr
	19:00	00:00	0.85 U/hr
			Total Basal 15.65 U/day

Temporary Basal Enabled ON

Bolus Settings

When using Automated Mode, the main adjustable setting that directly impacts automated insulin delivery is Target Glucose. The SmartBolus Calculator settings below impact suggested bolus doses in both Automated and Manual Mode.

	Start Time	End Time	Target Glucose	Correct Above
Target Glucose & Correct Above	00:00	00:00	6.1 mmol/L	6.1 mmol/L


	Start Time	End Time	1 U of Insulin Covers
Insulin to Carb (IC) Ratio	00:00	16:00	9 g of carbs
	16:00	21:00	10 g of carbs
	21:00	00:00	8 g of carbs

	Start Time	End Time	1 U of Insulin Lowers Glucose By
Correction Factor	00:00	00:00	2.8 mmol/L

Duration of Insulin Action	3 hours
----------------------------	---------

Max Bolus	8 U
Extended Bolus	ON
Min Glucose for Calculation	3.9 mmol/L
Reverse Correction	OFF

GETTING STARTED ON OMNIPOD DISCOVER



Create an HCP account

All staff who wish to use Omnipod Discover must have an Omnipod HCP account.

- 1 Admin will invite you into **Omnipod Discover**. (Note: If you are first admin of the clinic, you will be invited by Insulet)
- 2 Click the **link** in your **invite email**
- 3 Follow the steps to **set up the account**
- 4 **Sign in** to your account



Navigate to Omnipod Discover

- 1 **Access Omnipod Discover** via your HCP account
- 2 Sign the **User Agreement**



Invite patients

- 1 From Patient Directory, click **Invite Patient**
- 2 Enter patient's information
- 3 Click **Invite**




Invite staff

Omnipod Discover clinic admin privileges are required to invite and manage staff.

- 1 From Staff Directory, click **Invite Staff**
- 2 Enter team member's information
- 3 Click **Invite**

EMPOWER YOUR OMNIPOD 5 PATIENTS

ACTIONABLE* DATA INSIGHTS



Screens are examples, for illustrative purposes only.

References:

*The term "Actionable" in this context refers to acting on insights to make lifestyle changes such as adjustments in diet, physical activity, and other daily habits. It does not imply or recommend making changes to device settings.

1. Brown S, et al. *Diabetes Care*. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6–70 yrs [adults/adolescents (n=128; aged 14–70 yrs) children (n=112; aged 6–13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL or >10 mmol/L in adults/adolescents and children, ST vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, $P<0.0001$, respectively. Mean time <70 mg/dL or <3.9 mmol/L in adults/adolescents and children, ST vs. 3-month Omnipod 5: 2.9% vs. 1.3%, $P<0.0001$; 2.2% vs. 1.8%, $P=0.8153$, respectively. Results measured by CGM. Study funded by Insulet. 2. Sherr JL, et al. *Diabetes Care*. 2022; 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2–5.9 yrs. Study included a 14-day ST phase followed by a 3-month Omnipod 5 HCL phase. Mean time >180 mg/dL or >10 mmol/L in very young children (2–5.9 yrs) as measured by CGM: ST = 39.4%, 3-month Omnipod 5 = 29.5%, $P<0.0001$. Mean time <70 mg/dL or <3.9 mmol/L in very young children (2–5.9 yrs) as measured by CGM: ST = 3.43%, 3-month Omnipod 5 = 2.46%, $P=0.0204$. Results measured by CGM. Study funded by Insulet.



The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with compatible U100 rapid acting insulin.

Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Automated mode requires compatible sensor. Compatible sensors are sold and Prescribed separately. Sensor availability may vary per country or region.

Omnipod Discover is a retrospective data analytics and reporting system intended for Omnipod 5 System users or their caregivers and their healthcare providers for the analysis of glucose and insulin delivery data in home and healthcare settings. It is intended as supplemental data for the users to support diabetes management and aid healthcare providers in patient care. Omnipod Discover is not intended for people with diabetes in acute care settings or for real-time patient monitoring. The Omnipod Discover software platform is not intended to replace the primary real-time display of the sensor or insulin delivery data on the device, nor does it control any functions of the Omnipod 5 System. Any medical treatment decision or adjustments should not be made based on this software platform; a qualified healthcare professional needs to be consulted to make such decisions.

© 2026 Insulet Corporation. Insulet, Omnipod, the Omnipod logo, and Omnipod Discover are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

INS-ODD-12-2025-00002 V1.0